123531-52-2 Usage
General Description
Ethyl Imidazo[1,2-a]pyridine-3-carboxylate is a chemical compound with the molecular formula C10H8N2O2. It is a derivative of the imidazo[1,2-a]pyridine class of compounds, which are known for their diverse biological activities. This particular compound has been studied for its potential pharmacological properties, including its role as a potential inhibitor of enzymes involved in cellular processes. Its structure suggests that it may have potential use as a pharmaceutical agent, and further research is ongoing to explore its potential applications in drug development and medicinal chemistry. Additionally, its chemical properties make it a valuable tool for investigating the structure-activity relationships of imidazo[1,2-a]pyridine derivatives and their biological effects.
Check Digit Verification of cas no
The CAS Registry Mumber 123531-52-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,5,3 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 123531-52:
(8*1)+(7*2)+(6*3)+(5*5)+(4*3)+(3*1)+(2*5)+(1*2)=92
92 % 10 = 2
So 123531-52-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H10N2O2/c1-2-14-10(13)8-7-11-9-5-3-4-6-12(8)9/h3-7H,2H2,1H3
123531-52-2Relevant articles and documents
Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties
Lee, Jung Wuk,Park, Jiwon,Kim, Jina,Kim, Jihyung,Choi, Changyu,Min, Kyung Hoon
, (2021/03/14)
Tumor-associated macrophages (TAMs) are predominantly associated with tumor growth. Colony-stimulating factor 1 receptor (CSF1R) acts as a key regulator of TAM survival and differentiation and is a molecular target for cancer therapies. Herein, novel CSF1
IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS)
-
Page/Page column 88; 102, (2015/02/02)
The invention provides a compound of formula (I) (Formula (I)) or a tautomeric form, stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein R2, R3, R4, Ra, Rb
